Unknown PHASE2 INTERVENTIONAL 1-arm NCT04827004

A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma

A Open-label, Single-center, Single-arm Phase II Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Conditions Diffuse Large B-cell Lymphoma

Interventions Anlotinib Hydrochloride Capsules

Updated 4 times since 2021 Last updated: Mar 30, 2021 Started: Apr 30, 2021 Primary completion: Dec 31, 2022 Completion: Dec 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Diffuse Large B-cell Lymphoma, this trial is ongoing. The trial is conducted by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and has accumulated 4 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Feb 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status
May 2021 — Feb 2023 [monthly]

Not Yet Recruiting PHASE2

First recorded

Apr 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Data source: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China